Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | NOS2 | P35228 | 4/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.36 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.36 |
| ▸ | CNR1 | P21554 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.35 |
| ▸ | NOS1 | P29475 | 2/20 | 0.35 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | GPR139 | Q6DWJ6 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6295151 | 0.87 | NOS2 (0.44) | POLBKMT2ANOS2HCRTR1ALDH1A1 | |
| SCHEMBL6296163 | 0.77 | NOS2 (0.46) | POLBKMT2ANOS2ALDH1A1NOS1 | |
| SCHEMBL6295191 | 0.77 | NOS2 (0.46) | POLBNOS2ALDH1A1KDM4E | |
| SCHEMBL6296231 | 0.77 | NOS2 (0.46) | POLBNOS2ALDH1A1KDM4E | |
| SCHEMBL6296419 | 0.76 | NOS2 (0.46) | POLBNOS2ALDH1A1KDM4ECYP3A4 | |
| SCHEMBL6295163 | 0.76 | NOS2 (0.46) | POLBNOS2ALDH1A1KDM4ECYP3A4 | |
| SCHEMBL6835069 | 0.76 | NOS2 (0.38) | KMT2ANOS2NOS1 | |
| SCHEMBL5190101 | 0.75 | POLB (0.46) | POLBMEN1KMT2AALDH1A1GPR139 | |
| SCHEMBL5193272 | 0.74 | POLB (0.46) | TP53POLBKMT2ANOS2 | |
| SCHEMBL6296314 | 0.74 | NOS2 (0.52) | NOS2NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030092678-A1 | N-heterocyclic derivatives as NOS inhibitors | BERLEX LABORATORIES, INC. (US) | 2003-05-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030092678-A1 | N-heterocyclic derivatives as NOS inhibitors | NOS1, NOS2, NOS3 | TP53 4265/4885POLB 1328/4885MEN1 2172/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.